Compare SLVM & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLVM | AGIO |
|---|---|---|
| Founded | 1898 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2021 | 2013 |
| Metric | SLVM | AGIO |
|---|---|---|
| Price | $43.08 | $28.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $54.00 | $38.88 |
| AVG Volume (30 Days) | 270.4K | ★ 1.3M |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.15% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.24 | N/A |
| Revenue | ★ $3,351,000,000.00 | $43,011,000.00 |
| Revenue This Year | $0.93 | $76.75 |
| Revenue Next Year | $1.54 | $170.73 |
| P/E Ratio | $13.38 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.09 | $22.24 |
| 52 Week High | $61.31 | $46.00 |
| Indicator | SLVM | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.98 | 45.65 |
| Support Level | $41.08 | $26.64 |
| Resistance Level | $44.05 | $29.69 |
| Average True Range (ATR) | 1.52 | 1.34 |
| MACD | 0.19 | -0.56 |
| Stochastic Oscillator | 70.28 | 32.88 |
Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills. It produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers, and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.